Durvalumab and enfortumab vedotin improved outcomes in bladder cancer trial

MedPage Today reported that the phase III VOLGA trial found perioperative durvalumab plus enfortumab vedotin improved outcomes for people with muscle-invasive bladder cancer who were ineligible for or declined cisplatin. The trial included 695 patients. At 24 months, event-free survival was 63.5% with the combination and 45.1% with surgery alone. Thomas Powles presented the results at the European Society for Medical Oncology congress, and the findings were published in the New England Journal of Medicine.

Adding tremelimumab to the combination also improved event-free survival versus the control group, but the trial had not demonstrated an overall survival improvement for the three-drug regimen. Grade 3 or higher adverse events occurred in 71.1% of patients receiving durvalumab and enfortumab vedotin, 79.5% receiving the three-drug regimen, and 50.2% in the control group.